Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute

Kohei Edamura, Takashi Saika, Takashi Senoh, Fumihito Koizumi, Daisuke Manabe, Shin Ebara, Haruki Kaku, Teruhiko Yokoyama, Fernando Abarzua, Atsushi Nagai, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100% for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81% 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93% and 100% cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79% rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease. Copyright

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalActa Medica Okayama
Volume59
Issue number5
Publication statusPublished - Oct 2005

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Survival Rate
Therapeutics
Surgery
Radiation
Prostatectomy
Disease-Free Survival
Radiotherapy
Survival
Neoplasms

Keywords

  • Cohort
  • Long-term
  • Outcome
  • Prostate carcinoma
  • Retrospective

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Edamura, K., Saika, T., Senoh, T., Koizumi, F., Manabe, D., Ebara, S., ... Kumon, H. (2005). Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. Acta Medica Okayama, 59(5), 195-199.

Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. / Edamura, Kohei; Saika, Takashi; Senoh, Takashi; Koizumi, Fumihito; Manabe, Daisuke; Ebara, Shin; Kaku, Haruki; Yokoyama, Teruhiko; Abarzua, Fernando; Nagai, Atsushi; Nasu, Yasutomo; Tsushima, Tomoyasu; Kumon, Hiromi.

In: Acta Medica Okayama, Vol. 59, No. 5, 10.2005, p. 195-199.

Research output: Contribution to journalArticle

Edamura, K, Saika, T, Senoh, T, Koizumi, F, Manabe, D, Ebara, S, Kaku, H, Yokoyama, T, Abarzua, F, Nagai, A, Nasu, Y, Tsushima, T & Kumon, H 2005, 'Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute', Acta Medica Okayama, vol. 59, no. 5, pp. 195-199.
Edamura K, Saika T, Senoh T, Koizumi F, Manabe D, Ebara S et al. Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. Acta Medica Okayama. 2005 Oct;59(5):195-199.
Edamura, Kohei ; Saika, Takashi ; Senoh, Takashi ; Koizumi, Fumihito ; Manabe, Daisuke ; Ebara, Shin ; Kaku, Haruki ; Yokoyama, Teruhiko ; Abarzua, Fernando ; Nagai, Atsushi ; Nasu, Yasutomo ; Tsushima, Tomoyasu ; Kumon, Hiromi. / Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. In: Acta Medica Okayama. 2005 ; Vol. 59, No. 5. pp. 195-199.
@article{8dba0f48e1b44b1f868b8d79a9eb0562,
title = "Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute",
abstract = "This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100{\%} for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81{\%} 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93{\%} and 100{\%} cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79{\%} rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease. Copyright",
keywords = "Cohort, Long-term, Outcome, Prostate carcinoma, Retrospective",
author = "Kohei Edamura and Takashi Saika and Takashi Senoh and Fumihito Koizumi and Daisuke Manabe and Shin Ebara and Haruki Kaku and Teruhiko Yokoyama and Fernando Abarzua and Atsushi Nagai and Yasutomo Nasu and Tomoyasu Tsushima and Hiromi Kumon",
year = "2005",
month = "10",
language = "English",
volume = "59",
pages = "195--199",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute

AU - Edamura, Kohei

AU - Saika, Takashi

AU - Senoh, Takashi

AU - Koizumi, Fumihito

AU - Manabe, Daisuke

AU - Ebara, Shin

AU - Kaku, Haruki

AU - Yokoyama, Teruhiko

AU - Abarzua, Fernando

AU - Nagai, Atsushi

AU - Nasu, Yasutomo

AU - Tsushima, Tomoyasu

AU - Kumon, Hiromi

PY - 2005/10

Y1 - 2005/10

N2 - This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100% for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81% 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93% and 100% cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79% rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease. Copyright

AB - This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100% for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81% 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93% and 100% cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79% rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease. Copyright

KW - Cohort

KW - Long-term

KW - Outcome

KW - Prostate carcinoma

KW - Retrospective

UR - http://www.scopus.com/inward/record.url?scp=31344440506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344440506&partnerID=8YFLogxK

M3 - Article

C2 - 16286958

AN - SCOPUS:31344440506

VL - 59

SP - 195

EP - 199

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -